Oncology – Brain
RCT | Upfront radiosurgery reduces tumor volume vs. a wait-and-scan approach in small- to medium-sized vestibular schwannoma
7 Aug, 2023 | 14:40h | UTCUpfront Radiosurgery vs a Wait-and-Scan Approach for Small- or Medium-Sized Vestibular Schwannoma: The V-REX Randomized Clinical Trial – JAMA (free for a limited period)
See also: Visual Abstract
Commentary on Twitter
Among patients with small or medium vestibular schwannoma, a treatment strategy consisting of upfront radiosurgery was more effective at reducing tumor volume at 4 years than was the initial wait-and-scan approach. https://t.co/Qv3YZVsq2Q pic.twitter.com/aNeu7MJfl0
— JAMA (@JAMA_current) August 2, 2023
Phase 2 Study | BRAF-MEK inhibition in BRAF-mutated papillary craniopharyngiomas leads to tumor volume reduction
13 Jul, 2023 | 13:02h | UTCBRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Rare Brain Tumor Responds to Targeted Tumor Treatment with ‘Unprecedented’ Success – Mass General Brigham
Commentary on Twitter
Genetic analysis has shown the presence of activating BRAF mutations in 94% of papillary craniopharyngiomas. A phase 2 study showed partial response or better in 15 of 16 previously untreated patients. Read the full study: https://t.co/UOjerJ17s3
— NEJM (@NEJM) July 12, 2023
RCT | Vorasidenib enhances PFS in IDH1/2-mutant low-grade glioma, trial methods debated online
7 Jun, 2023 | 14:04h | UTCVorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Vorasidenib Delays Disease Progression or Death in Patients With Grade 2 IDH-Mutated Glioma – The ASCO Post
Commentary on Twitter questioning study methodology (thread – click for more)
This is a rather troubling study. The fact that it got published in @NEJM is concerning, to say the least
Astonishing cost of $16 000/month for a drug administered continuously until disease progression in a trial with a dubious endpoint and flawed design
Here are my thoughts: https://t.co/E3QtZfEyQw
— Stanislav (Stas) Lazarev, MD (@StasLazarev) June 5, 2023
RCT | Gefitinib plus chemotherapy vs. Gefitinib alone in untreated EGFR-mutant NSCLC with brain metastases
16 May, 2023 | 14:30h | UTC
Commentary on Twitter
RCT: In patients with untreated EGFR-mutated non-small cell lung cancer with brain metastases, gefitinib + chemo improved survival and PFS vs gefitinib, with manageable adverse events, and may be a viable first-line treatment. #NSCLC https://t.co/Oe6zHYVsPV pic.twitter.com/oUvs12pYS7
— JAMA Network Open (@JAMANetworkOpen) February 9, 2023
RCT | Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma
12 May, 2023 | 13:18h | UTCNews Release: ChemoID platform-predicted treatments lead to longer survival for glioblastoma patients – University of Cincinnati
Commentary on Twitter
Online now: Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial https://t.co/y5GYCCgg3b
— Cell Reports Medicine (@CellRepMed) May 3, 2023
Neurosurgical interventions for cerebral metastases of solid tumors
11 May, 2023 | 11:48h | UTC
Review | Glioblastoma and other primary brain malignancies in adults
24 Feb, 2023 | 13:54h | UTCArticle: Glioblastoma and Other Primary Brain Malignancies in Adults: A Review – JAMA (free for a limited period)
Audio clinical review: Glioblastoma and Other Primary Brain Malignancies in Adults – JAMA
Commentary on Twitter
Review summarizes current evidence regarding diagnosis and treatment of primary malignant brain tumors in adults. https://t.co/pNKio61bN5
— JAMA (@JAMA_current) February 21, 2023
M-A | Association of brain metastases with survival in patients with limited or stable extracranial disease
24 Feb, 2023 | 13:34h | UTC
RCT | Adjuvant temozolomide with or without interferon alfa in patients with newly diagnosed high-grade gliomas
30 Jan, 2023 | 00:27h | UTCCommentary: Interferon Alfa Improves Upon Standard Care in High Grade Glioma – Cancer Therapy Advisor
Commentary on Twitter
This phase 3 clinical trial demonstrated interferon alfa + temozolomide prolonged survival time in patients with newly diagnosed high-grade gliomas by median 8 months (18% vs 9% 5yr overall survival), especially with MGMT promoter unmethylated tumors. https://t.co/2yOssnF97G
— JAMA Network Open (@JAMANetworkOpen) January 27, 2023
SR | Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation
19 Jan, 2023 | 14:09h | UTC
Cohort Study | Brain cancer after radiation exposure from CT examinations of children and young adults
18 Jan, 2023 | 14:36h | UTCBrain cancer after radiation exposure from CT examinations of children and young adults: results from the EPI-CT cohort study – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries:
CT brain cancer risk quantified for children and young adults – medwire News
NCCN Guideline | Pediatric central nervous system cancers
12 Jan, 2023 | 13:11h | UTCEditorial: ASCO Living Guidelines: The Next Frontier
Single-arm phase 1b study | Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma.
11 Nov, 2022 | 13:00h | UTCChronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial – The Lancet Oncology (link to abstract – $ for full-text)
Phase 2 RCT | Concurrent Bevacizumab and reirradiation vs. Bevacizumab alone as treatment for recurrent glioblastoma.
9 Nov, 2022 | 12:21h | UTCNRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Bevacizumab Plus Reirradiation Improves PFS in Glioblastoma Multiforme – OncLive
Post-trial follow-up | Long-term outcomes with stereotactic radiosurgery vs. whole-brain RT for resected brain metastasis.
7 Nov, 2022 | 12:22h | UTCAssociation of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis: A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary: Survivors face less late cognitive deterioration after stereotactic radiosurgery than WBRT – medwire News
Original Study: Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In pts w limited brain mets after surgical resection, secondary analysis of rand phase 3 trial shows more patients declined significantly in 1 or more cognitive tests with whole brain radiation therapy (WBRT) vs stereotactic radiosurgery (SRS) https://t.co/6nSCO5kSpW #BTSM
— JAMA Oncology (@JAMAOnc) October 22, 2022
Isocitrate dehydrogenase mutant gliomas: consensus review on diagnosis, management, and future directions.
17 Oct, 2022 | 12:31h | UTC
M-A | Extent of tumor resection and survival in pediatric patients with high-grade gliomas.
17 Aug, 2022 | 14:00h | UTC
Commentary on Twitter
In this systematic review and meta-analysis of pediatric high-grade gliomas, gross total resection was associated with better overall survival than subtotal resection and biopsy. https://t.co/QpKiDKpYYs
— JAMA Network Open (@JAMANetworkOpen) August 16, 2022
ASTRO Guideline | Radiation therapy for IDH-mutant grade 2 and grade 3 diffuse glioma.
29 Jul, 2022 | 12:33h | UTC
Single-arm study | Intensive multimodality therapy for extraocular retinoblastoma.
21 Jul, 2022 | 12:25h | UTCIntensive Multimodality Therapy for Extraocular Retinoblastoma: A Children’s Oncology Group Trial (ARET0321) – Journal of Clinical Oncology (link to abstract – $ for full-text)
The Global Retinoblastoma Outcome Study | A prospective, cluster-based analysis of 4,064 patients from 149 countries.
14 Jul, 2022 | 12:16h | UTCInvited Commentary: Retinoblastoma as a lens for correctable disparities worldwide – The Lancet Global Health
Phase II RCT | Proton craniospinal irradiation vs. photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis.
13 Jul, 2022 | 11:09h | UTCRandomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis – Journal of Clinical Oncology (link to abstract – $ for full-text)
Phase 1 single-arm study | Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma.
4 Jul, 2022 | 12:08h | UTCOncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Oncolytic Virus Infusion Promising as Brain-Stem Glioma Treatment — Phase I trial shows encouraging OS in children with diffuse intrinsic pontine glioma – MedPage Today (free registration required)
Joint final report of Phase III trials demonstrate positive outcomes from combination of PCV chemotherapy and RT in patients with anaplastic oligodendroglial tumors.
30 Jun, 2022 | 10:16h | UTC
M-A: Stereotactic radiosurgery vs. whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer.
30 May, 2022 | 10:41h | UTCStereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis – The Lancet Oncology (link to abstract – $ for full-text)
Cohort Study: Effect of awake craniotomy in glioblastoma in eloquent areas.
23 May, 2022 | 00:40h | UTCEffect of awake craniotomy in glioblastoma in eloquent areas (GLIOMAP): a propensity score-matched analysis of an international, multicentre, cohort study – the Lancet Oncology (link to abstract – $ for full-text)
Commentary: Neurologic and Survival Outcomes After Awake Craniotomy for Glioblastoma – The ASCO Post
Commentary on Twitter
In matched cohort of patients with glioblastoma, awake craniotomy resulted in fewer neurological deficits at 3 mo and 6 mo post-surgery than asleep resection, and longer mOS (17.0 mo versus 14.0 mo; P =0.0005), and mPFS (9.0 mo versus 7.3 mo; P = 0.006) https://t.co/S1fdRTxYDg
— NatureRevClinOncol (@NatRevClinOncol) May 19, 2022